Pharmaceuticals News and Research

RSS

Forest Pharmaceuticals to pay $300 million as penalty for criminal actions

The U.S. Food and Drug Administration (FDA), working in close coordination with the U.S. Department of Justice (USDOJ), today announced that Forest Pharmaceuticals, Inc. entered into a plea agreement in which the company accepted responsibility for criminal actions including distribution of an unapproved new drug, distribution of a misbranded drug, and obstruction of an FDA inspection.

16 Sep 2010

BioCryst Pharmaceuticals announces BCX4208 compound results for treating gout

BioCryst Pharmaceuticals, Inc. announced positive top-line results from its randomized, double-blind, multi-center, placebo-controlled Phase 2 study designed to evaluate the urate-lowering activity and safety of several doses of BCX4208 alone and in combination with selected doses of allopurinol administered once-daily.

16 Sep 2010

Researchers identify role of bile acid in lifespan extension

The human quest for longer life may be one step closer, thanks to research from Concordia University. Published in the journal Aging, a new study is the first to identify the role of a bile acid, called lithocholic acid (LCA), in extending the lifespan of normally aging yeast. The findings may have significant implications for human longevity and health, as yeast share some common elements with people.

16 Sep 2010

Generics drugs in Medicare program saved $33 billion in 2007: CBO

New research released today by the Congressional Budget Office (CBO) found that the use of generic medications rather than brand-name medications in Medicare Part D saved beneficiaries and the program about $33 billion in 2007, while an additional $14 billion in savings is expected as first-time generics enter the market through 2012.

16 Sep 2010

Anonymous Funding promotes drug development for Fragile X syndrome treatment

Funding from an anonymous wealthy family has been the secret to progress, at long last, in developing drugs that show promise for helping millions of people worldwide with Fragile X syndrome, the most common genetic cause of autism. That's the topic of a fascinating article in the current issue of Chemical & Engineering News (C&EN), ACS' weekly newsmagazine.

16 Sep 2010

Researchers develop infected tissue model for Aganocide compounds

Two common and important human pathogens, P. aeruginosa and S. aureus, are implicated in many clinical diseases of the eye and skin, including keratitis and impetigo, respectively. Infections with their associated toxins can result in the destruction of underlying tissue.

16 Sep 2010

Abbott issues statement in response to FDA's mixed vote for weight loss medication sibutramine

The U.S. Food and Drug Administration today held an Endocrinologic and Metabolic Drugs Advisory Committee to review the results of SCOUT and the weight loss medication sibutramine (sold as Meridia® in the United States).

16 Sep 2010

Advanced Life Sciences participates as exhibitor in 50th ICAAC

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today participated in the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy

16 Sep 2010

bluebird bio publishes LentiGlobin gene therapy clinical trial data results

bluebird bio an emerging leader in the development of innovative gene therapies for severe genetic disorders, today announced publication in the journal Nature of its promising Phase 1/2 data highlighting positive results of LentiGlobin gene therapy treatment in a young adult with severe beta-thalassemia, a blood disorder that is one of the most frequent inherited diseases.

16 Sep 2010

Orexo signs agreement with NewBridge for Abstral drug sale

Orexo AB announces today that an exclusive licensing and distribution agreement has been signed with NewBridge Pharmaceuticals for Abstral, Orexo´s product for the treatment of breakthrough cancer pain.

16 Sep 2010

Tetraphase Pharmaceuticals presents preclinical data of TP-434 antibacterial drug

Tetraphase Pharmaceuticals, Inc., today presented encouraging preclinical data for its lead drug candidate, TP-434, which showed the potent antibacterial activity of TP-434 against a very broad spectrum of susceptible and multidrug-resistant pathogens.

16 Sep 2010

Chimerix presents promising clinical data for CMX001 in late-breaker poster session at 50th ICAAC

Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today presented promising clinical data for CMX001 in a late-breaker poster session at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy.

16 Sep 2010

Researchers find NCT analogs show antimicrobial, anticoagulant activity

Catheter-related bacteremia can be a significant cause of sickness and death for hemodialysis patients. The anticoagulant heparin is commonly used as a catheter lock solution to prevent thrombosis; however has limited antimicrobial activity.

16 Sep 2010

New clinical trial supports benefits of turmeric extract to people with osteoarthritis

A new clinical trial supports the benefits to people with osteoarthritis who used a unique extract of turmeric. Scientists in Italy have studied the pain-relief, increased flexibility, and other effects of a special, patented extract of the roots of turmeric, the flavorful spice that has been used for centuries as a traditional remedy. Turmeric formulations have shown a wide range of safety and significant scientific and clinical benefits in recent animal research and human clinical trials.

16 Sep 2010

Relypsa announces positive results from Phase 2 clinical trial of RLY5016

Relypsa, Inc., a biopharmaceutical company developing non-absorbed polymeric drugs, today announced positive results from the company's PEARL-HF study, a Phase 2 clinical trial of the company's lead compound, RLY5016. These data were presented by Dr. Bertram Pitt, Professor of Medicine Emeritus, Division of Medicine at the University of Michigan School of Medicine, during the Late-Breaking Clinical Trials Session in an oral presentation titled "The PEARL-HF (Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple-Dose To Evaluate the Effects of RLY5016 in Heart Failure Patients) Trial" at the 14th Annual Scientific Meeting of the Heart Failure Society of America held in San Diego, CA September 13-15, 2010.

16 Sep 2010

Novel Compound's NVC-422 broad-spectrum antimicrobial agent kills P. mirabilis bacteria in catheters

Patients fitted with long-term bladder catheters often face a potentially serious complication caused by a Gram-negative bacteria Proteus mirabilis that can colonize the catheters.

16 Sep 2010

Researchers investigate antimicrobial activity of Aganocide compounds against H1N1

Fears over the influenza A virus (H1N1; sometimes referred to as swine flu) have motivated researchers to investigate the antimicrobial activity of the Aganocide compounds against viruses. In a study presented at this year's Interscience Conference on Antimicrobial Agents and Chemotherapy, a team led by Professor Markus Nagl, MD of Medical University of Innsbruck and including D. Debabov, PhD and K. Hybiske, PhD of NovaBay Pharmaceuticals evaluated the in vitro virucidal activity of three compounds: N-chlorotaurine, a compound produced by human phagocytes; and two NCT analogs, NVC-612 and NVC-422.

16 Sep 2010

NPS Pharmaceuticals intends to offer public offering of common stock

NPS Pharmaceuticals, Inc. today announced that it intends to offer and sell approximately $41,290,000 of its common stock in an underwritten public offering.

16 Sep 2010

Polydex Pharmaceuticals reports decrease in sales for second quarter 2011

Polydex Pharmaceuticals Limited reports financial results for the second quarter of fiscal 2011, the three-month period ending July 31, 2010.

16 Sep 2010

Access Pharmaceuticals launches product website for MuGard

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has launched www.MuGard.com. The patient- and healthcare professional- focused site is a comprehensive resource offering educational material on oral mucositis, patient analysis, MuGard product and how-to-order information.

15 Sep 2010